WO2004050883A3 - Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine - Google Patents

Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine Download PDF

Info

Publication number
WO2004050883A3
WO2004050883A3 PCT/PL2003/000135 PL0300135W WO2004050883A3 WO 2004050883 A3 WO2004050883 A3 WO 2004050883A3 PL 0300135 W PL0300135 W PL 0300135W WO 2004050883 A3 WO2004050883 A3 WO 2004050883A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
liver fluke
ubiquitin
hepatitis
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2003/000135
Other languages
French (fr)
Other versions
WO2004050883A2 (en
Inventor
Andrzej B Legocki
Katarzyna Miedzinska
Magdalena Czaplinska
Anna Modelska
Tomasz Pniewski
Andrzej Plucienniczak
Malgorzata Kezik
Anna Porebska
Halina Wedrychowicz
Juliusz Mieszczanek
Luiza Jedlina-Panasiuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST OF BIOORG CHEMISTRY
INST OF BIOTECHNOLOGY ANTIBIOT
INST OF PARASITOLOGY POLISH AC
Original Assignee
INST OF BIOORG CHEMISTRY
INST OF BIOTECHNOLOGY ANTIBIOT
INST OF PARASITOLOGY POLISH AC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF BIOORG CHEMISTRY, INST OF BIOTECHNOLOGY ANTIBIOT, INST OF PARASITOLOGY POLISH AC filed Critical INST OF BIOORG CHEMISTRY
Priority to AU2003295293A priority Critical patent/AU2003295293B2/en
Priority to EP03786456A priority patent/EP1613752B1/en
Priority to NZ540582A priority patent/NZ540582A/en
Priority to DE60314017T priority patent/DE60314017T2/en
Priority to DK03786456T priority patent/DK1613752T3/en
Publication of WO2004050883A2 publication Critical patent/WO2004050883A2/en
Publication of WO2004050883A3 publication Critical patent/WO2004050883A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The topic of the present invention is a chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, sequence, construct, plant cell, a method for the production of the chimaeric protein and transgenic plant, the transgenic plant, and the application of transgenic plants to produce oral vaccines, pharmaceutical composition, vaccination against the liver fluke and a method for inducing immunity against liver fluke infections in mammals. In general, the present invention relates to a method for inducing an immune response, encompassing the application of vaccines through the gastrointestinal tract. The topics of the present invention serve to produce oral vaccines against the liver fluke.
PCT/PL2003/000135 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine Ceased WO2004050883A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003295293A AU2003295293B2 (en) 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
EP03786456A EP1613752B1 (en) 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
NZ540582A NZ540582A (en) 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
DE60314017T DE60314017T2 (en) 2002-12-04 2003-12-04 CHIMERIC PROTEIN CONTAINS THE CYSTEIN PROTEASE FROM THE LARGE LIVERGEL FUSIONED TO THE HEPATITIS B CORE PROTEIN OR UBIQUITIN; PLANTS EXPRESSING THIS PROTEIN, AND THEIR USE AS VACCINE
DK03786456T DK1613752T3 (en) 2002-12-04 2003-12-04 Molecule of nucleic acid, plant cell, process for the production of chimeric protein, process for the production of transgenic plant, transgenic plant, use of transgenic plant, pharmaceutical composition, vaccine against liver disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL357517A PL201419B1 (en) 2002-12-04 2002-12-04 Chimeric protein, sequence, construction, vegetable cell, method of obtaining chimeric protein and transgenic plant, transgenic plant, application of transgenic plant and chimeric protein
PLP-357517 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050883A2 WO2004050883A2 (en) 2004-06-17
WO2004050883A3 true WO2004050883A3 (en) 2004-11-04

Family

ID=32464755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2003/000135 Ceased WO2004050883A2 (en) 2002-12-04 2003-12-04 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine

Country Status (9)

Country Link
EP (1) EP1613752B1 (en)
AT (1) ATE362988T1 (en)
AU (1) AU2003295293B2 (en)
DE (1) DE60314017T2 (en)
DK (1) DK1613752T3 (en)
ES (1) ES2288223T3 (en)
NZ (1) NZ540582A (en)
PL (1) PL201419B1 (en)
WO (1) WO2004050883A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196114B1 (en) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Inclusion bodies as antigenes in oral immunization of animals
US20070292490A1 (en) * 2004-06-25 2007-12-20 Valentin Negrouk Production of tissue factor in plants
JP5832445B2 (en) * 2009-12-10 2015-12-16 エスコラ スペリオール アグラリア デ コインブラＥｓｃｏｌａ Ｓｕｐｅｒｉｏｒ Ａｇｒａｒｉａ Ｄｅ Ｃｏｉｍｂｒａ Immunogens, their preparation and use in polyclonal antibody production systems
WO2014124047A1 (en) 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
CN109641938A (en) 2016-05-27 2019-04-16 中央研究院 Derived from Arginine-rich structural domain through modified antimicrobial peptide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006658A1 (en) * 1988-01-13 1989-07-27 The University Of North Carolina At Chapel Hill Immunogenic peptides
WO1994009142A1 (en) * 1992-10-21 1994-04-28 Mallinckrodt Veterinary, Inc. Vaccine containing a thiol protease
WO1994017820A1 (en) * 1993-02-05 1994-08-18 Daratech Pty. Ltd. Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same
WO1994028925A1 (en) * 1993-06-15 1994-12-22 Mallinckrodt Veterinary Inc. Vaccine containing a serine protease
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006658A1 (en) * 1988-01-13 1989-07-27 The University Of North Carolina At Chapel Hill Immunogenic peptides
WO1994009142A1 (en) * 1992-10-21 1994-04-28 Mallinckrodt Veterinary, Inc. Vaccine containing a thiol protease
WO1994017820A1 (en) * 1993-02-05 1994-08-18 Daratech Pty. Ltd. Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same
WO1994028925A1 (en) * 1993-06-15 1994-12-22 Mallinckrodt Veterinary Inc. Vaccine containing a serine protease
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KOFTA W ET AL: "Successful DNA immunisation of rats against fasciolosis", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 26, July 2000 (2000-07-01), pages 2985 - 2990, XP004199092, ISSN: 0264-410X *
SCHODEL F ET AL: "Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. Presentation of foreign epitopes", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 1, 26 January 1996 (1996-01-26), pages 91 - 96, XP004036853, ISSN: 0168-1656 *
SCHOEDEL F ET AL: "HEPATITIS B VIRUS CORE AND E ANTIGEN: IMMUNE RECOGNITION AND USE ASA VACCINE CARRIER MOIETY", INTERVIROLOGY, XX, XX, vol. 39, no. 1/2, 1996, pages 104 - 110, XP000891467, ISSN: 0300-5526 *
TARAR M R ET AL: "Expression of a human cytomegarovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 16, no. 3-4, 1996, pages 183 - 192, XP002973530, ISSN: 0928-8244 *
WEDRYCHOWICZ H ET AL: "INVESTIGATION OF CYSTEINE PROTEINASE AS A POTENTIAL VACCINE CANDIDATE AGAINST FASCIOLA HEPATICA INFECTION", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 73, September 2000 (2000-09-01), pages 272, XP000982901, ISSN: 0165-2478 *
WEDRYCHOWICZ H ET AL: "The immune response of rats to vaccination with the cDNA or protein forms of the cysteine proteinase of Fasciola hepatica.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 94, no. 1-2, 15 July 2003 (2003-07-15), pages 83 - 93, XP002291369, ISSN: 0165-2427 *

Also Published As

Publication number Publication date
DE60314017D1 (en) 2007-07-05
NZ540582A (en) 2008-05-30
WO2004050883A2 (en) 2004-06-17
DK1613752T3 (en) 2007-09-10
PL357517A1 (en) 2004-06-14
AU2003295293A1 (en) 2004-06-23
EP1613752B1 (en) 2007-05-23
ES2288223T3 (en) 2008-01-01
ATE362988T1 (en) 2007-06-15
DE60314017T2 (en) 2008-01-17
AU2003295293B2 (en) 2009-12-03
EP1613752A2 (en) 2006-01-11
PL201419B1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE489968T1 (en) PROTEOSOME-LIPOSACCHARIDE VACCINE ADJUVANT
HUP0301659A2 (en) Maize cellulose synthases and uses thereof
ATE350057T1 (en) VACCINE COMPOSITION
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2003028632A3 (en) Development of a preventive vaccine for filovirus infection in primates
CY2013025I1 (en) HETEROLOGOUS EXPRESSION OF NEISSERIA PROTEINS
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2002095023A3 (en) Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
MY128999A (en) Purification of hbv antigens for use in vaccines
WO2004050883A3 (en) Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
ATE354370T1 (en) INACTIVATED IMMUNOGENIC BACTERIAL WHOLE CELL COMPOSITIONS
EP1220864A4 (en) TRANSGENIC PRODUCED FUSION PROTEINS
WO2004050692A3 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
ATE349531T1 (en) ISOLATION AND CHARACTERIZATION OF THE CSA OPERON (ETEC-CS4 PILI) AND METHOD OF ITS APPLICATION
ATE427119T1 (en) RECOMBINANT RABIES VACCINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
NO20053328L (en) Immunization of fish with expressed proteins in plant cells.
NO20042429L (en) Novel immunogenic mimics of multimeric proteins
WO2004024756A3 (en) Orthopoxvirus antigens and use thereof
DK1423525T3 (en) Recombinant MVA capable of expressing HCV structural antigens
DE60239753D1 (en) VACCINATE AGAINST INFECTIOUS LACHSANEMIA VIRUS
DK1553979T3 (en) IHNV-G fusion protein for immunostimulation
WO2009094006A3 (en) Bordetella outer-membrane protein antigens and methods of making and using the same
AUPQ661600A0 (en) A nucleic acid construct and methods related thereto
ITRM20010332A1 (en) SUBUNITY VACCINES AND PROCEDURES FOR THEIR PRODUCTION.
WO2004058816A3 (en) Inclusion bodies for the oral vaccination of animals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003295293

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540582

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003786456

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003786456

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003786456

Country of ref document: EP